MedPath

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

Phase 2
Completed
Conditions
Asthma
Registration Number
NCT00096616
Lead Sponsor
Boehringer Ingelheim
Brief Summary

The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
113
Inclusion Criteria
  • Patient greater than or equal to 18 years of age,
  • non-smokers,
  • diagnosed with asthma, with an FEV1 less than or equal to 70 percent of predicted normal,
  • stable use of Beta agonist
  • daily use of inhaled steroids for one year
Exclusion Criteria
  • Patients with other significant diseases other than asthma, requiring oxygen,
  • intubated within 5 years,
  • asthma exacerbation within 6 weeks of trial,
  • use of unstable doses (greater than 10 mg/day of prednisone or equivalent) of steroids,
  • participating in another interventional trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
FEV1 area under the curve (AUC) 0 to 6 hours Peak FEV1
Secondary Outcome Measures
NameTimeMethod
FEV1 at each timepoint Peak FVC FVC at each timepoint FVC AUC 0-6 Adverse events Vital signs

Trial Locations

Locations (18)

Ben Taul General Hospital

🇺🇸

Houston, Texas, United States

North Shore University Hospital

🇺🇸

Manhasset, New York, United States

620 South 20th Street, NHB 104

🇺🇸

Birmingham, Alabama, United States

Southern California Clinical Trials

🇺🇸

Lakewood, California, United States

Johns Hopkins Asthma & Allergy

🇺🇸

Baltimore, Maryland, United States

Norwalk Hospital

🇺🇸

Norwalk, Connecticut, United States

Penn State University, Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

University of Wisconsin Hospital

🇺🇸

Madison, Wisconsin, United States

Spartanburg Medical Research

🇺🇸

Spartanburg, South Carolina, United States

NYU School of Medicine

🇺🇸

New York, New York, United States

Boehringer Ingelheim Investigational Site

🇺🇸

Charleston, South Carolina, United States

University of Miami School of Medicine

🇺🇸

Miami, Florida, United States

LSU MC-Sheveport

🇺🇸

Shreveport, Louisiana, United States

Brigham & Women's Hospital

🇺🇸

Boston, Massachusetts, United States

Wake Forest University, Center for Human Genomics

🇺🇸

Winston-Salem, North Carolina, United States

University of Texas Health Center at Tyler

🇺🇸

Tyler, Texas, United States

Cooper Green Hospital

🇺🇸

Birmingham, Alabama, United States

Division of Pulmonary & Critical Care Medicine

🇺🇸

Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath